Form 4: ARS Pharma CFO Granted 240,000 Stock Options

ARS Pharmaceuticals' Chief Financial Officer, Kathleen D. Scott, was granted 240,000 stock options with an exercise price of $11.49, vesting over 48 months.

Summary

• Kathleen D. Scott, Chief Financial Officer of ARS Pharmaceuticals, Inc. (SPRY), acquired 240,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was January 2, 2026.
• Each stock option has an exercise price of $11.49.
• The options will vest in 48 equal monthly installments, commencing from January 1, 2026.
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Kathleen D. Scott directly beneficially owns 240,000 derivative securities.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant) which is generally neutral to slightly positive as it aligns management incentives with shareholder interests, though it carries potential for future dilution.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's financial interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over 48 months promotes retention of key executive talent.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Future Outlook

The filing indicates a future vesting schedule for the granted stock options, with installments measured from January 1, 2026, over 48 months, and an expiration date of January 1, 2036. This suggests a long-term incentive structure for the Chief Financial Officer.

Industry Context

The grant of stock options to a Chief Financial Officer is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive compensation packages designed to attract, retain, and incentivize senior management by aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The 48-month vesting schedule is typical for executive equity awards, promoting long-term commitment and performance.
• Without specific peer company compensation data, a direct comparison of the size and terms of this grant to industry benchmarks is not possible based solely on this filing, but the structure is consistent with general industry norms.

Related Party Transactions

• The grant of 240,000 stock options to Kathleen D. Scott, the Chief Financial Officer, constitutes a transaction between the company and a related party (an executive officer).

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of executive interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a standard approach to compensation.

Next Steps

• The stock options will vest in 48 equal monthly installments, measured from January 1, 2026.

Key Dates

Keywords

ARS Pharmaceuticals, SPRY, Stock Options, Executive Compensation, Form 4, Insider Transaction, Kathleen Scott, CFO